Chengdu-headquartered biotech company HitGen Inc, which is backed by CDH Investments, is seeking to raise a total of 835 million yuan ($118 million) in its initial public offering (IPO) on China’s Nasdaq-like STAR Market.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
